Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/eurheartj/16.suppl_n.103 http://scihub22266oqcxt.onion/10.1093/eurheartj/16.suppl_n.103 8682054!ä!8682054 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\8682054.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Heart+J 1995 ; 16 Suppl N (ä): 103-6 Nephropedia Template TP {{tp|p=8682054|t=1995. Aldosterone escape during ACE inhibitor therapy in chronic heart failure |pdf=|usr=}}{{8682054}} gab.com Text Aldosterone escape during ACE inhibitor therapy in chronic heart failure JO: Eur Heart J http://www.kidney.de/pget.php?&tw=1&pmid=8682054 #FOAvip In the setting of chronic heart failure (CHF), therapy with angiotensin converting enzyme (ACE) inhibitors generally reduces serum aldosterone levels acutely. However, long-term ACE inhibition is associated with aldosterone suppression that is weak, variable, and unsustained, i.e. aldosterone 'escape'. Magnesium loss caused by aldosterone and by diuretics can contribute to coronary artery spasm and arrhythmias. Aldosterone can block noradrenaline uptake by the myocardium; extracellular catecholamines may lead to arrhythmias and ischaemia. Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF. Both angiotensin II and aldosterone may stimulate myocardial fibrosis, which is associated with a higher incidence of malignant ventricular arrhythmias. ACE inhibition initiated early in the progression of CHF may prevent development of patchy myocardial fibrosis and its inherent arrhythmias and thus reduce the incidence of sudden death. Spironolactone therapy added to the regimen of an ACE inhibitor and diuretic can induce natriuresis and magnesium retention, increase myocardial noradrenaline uptake, and reduce the incidence of arrhythmias. Twit Text FOAVip Aldosterone escape during ACE inhibitor therapy in chronic heart failure ????Eur Heart J http://www.kidney.de/pget.php?&tw=1&pmid=8682054 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=8682054 #FOAvip English Wikipedia <ref>{{Cite pmid|8682054}}</ref> Aldosterone escape during ACE inhibitor therapy in chronic heart failure #MMPMID8682054 Struthers AD Eur Heart J 1995[Dec]; 16 Suppl N (ä): 103-6 PMID8682054show ga In the setting of chronic heart failure (CHF), therapy with angiotensin converting enzyme (ACE) inhibitors generally reduces serum aldosterone levels acutely. However, long-term ACE inhibition is associated with aldosterone suppression that is weak, variable, and unsustained, i.e. aldosterone 'escape'. Magnesium loss caused by aldosterone and by diuretics can contribute to coronary artery spasm and arrhythmias. Aldosterone can block noradrenaline uptake by the myocardium; extracellular catecholamines may lead to arrhythmias and ischaemia. Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF. Both angiotensin II and aldosterone may stimulate myocardial fibrosis, which is associated with a higher incidence of malignant ventricular arrhythmias. ACE inhibition initiated early in the progression of CHF may prevent development of patchy myocardial fibrosis and its inherent arrhythmias and thus reduce the incidence of sudden death. Spironolactone therapy added to the regimen of an ACE inhibitor and diuretic can induce natriuresis and magnesium retention, increase myocardial noradrenaline uptake, and reduce the incidence of arrhythmias. |Aldosterone/*blood[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use[MESH] |Arrhythmias, Cardiac/blood/prevention & control[MESH] |Chronic Disease[MESH] |Drug Therapy, Combination[MESH] |Endomyocardial Fibrosis/blood/prevention & control[MESH] |Heart Failure/blood/*drug therapy[MESH] |Humans[MESH] |Long-Term Care[MESH] |Mineralocorticoid Receptor Antagonists/administration & dosage/adverse effects[MESH] |Myocardium/pathology[MESH] |Risk Factors[MESH] |Spironolactone/administration & dosage/adverse effects[MESH]Aldosterone escape during ACE inhibitor therapy in chronic heart failu(epmc).pdf DeepDyve Pubget Overpricing